For how we live.
Matched against DPP-4 inhibitors, GLP-1 users had slightly more diabetic retinopathy and more retinopathy procedures. Vision impairment and blindness did not differ — and the coding for those is poor.
A supplement approved on 26 August adds SURPASS-CVOT to the prescribing information and rewrites the eye warning so it is addressed to patients with a history of retinopathy rather than to patients with diabetes.
Pooling under 11,000 pregnancies, a meta-analysis found no statistically significant association either way, with the three underlying studies disagreeing on which direction the risk even points.
Semaglutide showed a sixfold reporting signal for polycystic ovary syndrome and a smaller but real alopecia signal. Dulaglutide and tirzepatide showed lower or no signal for the same reproductive events.
Pooling 24 studies out of 133 screened, researchers found hair shedding tied to rapid weight loss more than to the drugs directly — and a pattern that hits women disproportionately.
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.